The 24th Congress of the European Hematology Association (EHA) is a forum for original unpublished data, sharing ideas about hematological innovation, and disseminating evidence-based knowledge of primary clinical relevance. Evidera will be presenting the following poster: Patient Reported Experience from Part 2 of the First Time in Human Study of the BCMA Antibody Drug Conjugate Belantamab Mafotodin (GSK2857916) for Advanced Relapsed Refractory Multiple Myeloma (DREAMM-1). Presenters include: Popat R, Opalinska J, Eliason L, Willson J, Felber G, Ackert J, Correll J, Martin ML, Bruno A

Conference Website